Projekt

An open, multicentric phase II trial to evaluate the efficacy and safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for patients with relapsed or refractory multiple myeloma

Automatisch geschlossen · 2012 bis 2014

Driessen Christoph, Mey Ulrich, Hiendlmeyer Elke, Clavadetscher Luzia